Cognitive disorders associated with hospitalization of COVID-19: Results from an observational cohort study

Zhou, Jingqi; Liu, Chang; Sun, Yitang; Huang, Weishan; Ye, Kaixiong

doi:10.1016/j.bbi.2020.10.019

Cited by 52 publications

(52 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings expand a recent analysis with a smaller sample size of COVID-19 positive individuals from the UK Biobank. In this study, Zhou and colleagues showed that AD is the most significant risk factor for COVID-19 infection but its association with increased COVID-19 mortality was not investigated 34 . Here, we build on these earlier observations to show that AD is a major risk factor associated with COVID-19 mortality, after accounting for a large number of comorbidities.…”

Section: Discussionmentioning

confidence: 77%

“…Dementia has also been found to increase the risk of in-hospital mortality in a large crosssectional analysis of 20,133 patients already hospitalised for COVID-19 in the UK 14 , a finding later replicated by two later studies 15,33 . However, these studies mostly focussed on hospitalised In this study, Zhou and colleagues showed that AD is the most significant risk factor for COVID-19 infection but its association with increased COVID-19 mortality was not investigated 34 .…”

Section: A Close Relationship Between Covid-19 and Neurological Disormentioning

confidence: 95%

See 1 more Smart Citation

Alzheimer’s and Parkinson’s diseases predict different COVID-19 outcomes, a UK Biobank study

Travaglio

Popovic

et al. 2020

Preprint

View full text Add to dashboard Cite

In December 2019, a coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began infecting humans causing a novel disease, coronavirus disease 19 (COVID-19). This was first described in the Wuhan province of the People′s Republic of China. SARS-CoV-2 spread throughout the world causing a global pandemic. To date, thousands of cases of COVID-19 were reported in the United Kingdom, and over 45,000 patients have died. Some progress has been achieved in managing this disease, but the biological determinants of health, besides age, that affect COVID-19 infectivity and mortality are under scrutiny. Recent studies show that several medical conditions, including diabetes and hypertension, increase the risk of COVID-19 infection and death. The increased vulnerability of the elderly and those with comorbidities, together with the prevalence of neurodegenerative diseases with advanced age, led us to investigate the links between neurodegeneration and COVID-19. We analysed the primary health records of 13,338 UK individuals tested for COVID-19 between March and July 2020. We show that a pre-existing diagnosis of Alzheimer′s disease predicts the highest risk of COVID-19 infection and mortality among the elderly. In contrast, Parkinson′s disease patients were found to be at increased risk of infection but not mortality from COVID-19. We conclude that there are disease-specific differences in COVID-19 susceptibility among patients affected by neurodegenerative disorders.

show abstract

Section: Discussionmentioning

confidence: 77%

Section: A Close Relationship Between Covid-19 and Neurological Disormentioning

confidence: 95%

Alzheimer’s and Parkinson’s diseases predict different COVID-19 outcomes, a UK Biobank study

Travaglio

Popovic

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…These findings expand a recent analysis of 1091 COVID-19-positive individuals from the UK Biobank. In this study, Zhou and colleagues employed a logistic regression analysis of pre-existing conditions that are overrepresented in patients with COVID-19 and showed that AD was the most significant risk factor for COVID-19, although its association with increased COVID-19 mortality was not investigated [ 43 ]. Here, we build on these earlier observations to show that AD is a major risk factor associated with COVID-19 mortality after accounting for a large number of comorbidities.…”

Section: Discussionmentioning

confidence: 99%

Alzheimer’s and Parkinson’s Diseases Predict Different COVID-19 Outcomes: A UK Biobank Study

Travaglio

Popovic

et al. 2021

Geriatrics

View full text Add to dashboard Cite

In December 2019, a coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), began infecting humans, causing a novel disease, coronavirus disease 19 (COVID-19). This was first described in the Wuhan province of the People’s Republic of China. SARS-CoV-2 has spread throughout the world, causing a global pandemic. To date, thousands of cases of COVID-19 have been reported in the United Kingdom, and over 45,000 patients have died. Some progress has been achieved in managing this disease, but the biological determinants of health, in addition to age, that affect SARS-CoV-2 infectivity and mortality are under scrutiny. Recent studies show that several medical conditions, including diabetes and hypertension, increase the risk of COVID-19 and death. The increased vulnerability of elderly individuals and those with comorbidities, together with the prevalence of neurodegenerative diseases with advanced age, led us to investigate the links between neurodegeneration and COVID-19. We analysed the primary health records of 13,338 UK individuals tested for COVID-19 between March and July 2020. We show that a pre-existing diagnosis of Alzheimer’s disease predicts the highest risk of COVID-19 and mortality among elderly individuals. In contrast, Parkinson’s disease patients were found to have a higher risk of SARS-CoV-2 infection but not mortality from COVID-19. We conclude that there are disease-specific differences in COVID-19 susceptibility among patients affected by neurodegenerative disorders.

show abstract

“…Given the advanced age of most AD patients, it is unclear if AD itself can be a risk factor for the new SARS COV2 infection [ 74 , 75 ]. The effect of SARS COV2 infection on the brain will only be assessed in the long run.…”

Section: Microglia Calcium Channelsmentioning

confidence: 99%

Roles of Microglial Ion Channel in Neurodegenerative Diseases

Cojocaru

Burada

Bălșeanu

et al. 2021

JCM

View full text Add to dashboard Cite

As the average age and life expectancy increases, the incidence of both acute and chronic central nervous system (CNS) pathologies will increase. Understanding mechanisms underlying neuroinflammation as the common feature of any neurodegenerative pathology, we can exploit the pharmacology of cell specific ion channels to improve the outcome of many CNS diseases. As the main cellular player of neuroinflammation, microglia play a central role in this process. Although microglia are considered non-excitable cells, they express a variety of ion channels under both physiological and pathological conditions that seem to be involved in a plethora of cellular processes. Here, we discuss the impact of modulating microglia voltage-gated, potential transient receptor, chloride and proton channels on microglial proliferation, migration, and phagocytosis in neurodegenerative diseases.

show abstract

Cognitive disorders associated with hospitalization of COVID-19: Results from an observational cohort study

Cited by 52 publications

References 44 publications

Alzheimer’s and Parkinson’s diseases predict different COVID-19 outcomes, a UK Biobank study

Alzheimer’s and Parkinson’s diseases predict different COVID-19 outcomes, a UK Biobank study

Alzheimer’s and Parkinson’s Diseases Predict Different COVID-19 Outcomes: A UK Biobank Study

Roles of Microglial Ion Channel in Neurodegenerative Diseases

Contact Info

Product

Resources

About